Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 72316-17-7 | MDL No. : | MFCD03427284 |
Formula : | C9H11BO2 | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | N/A |
M.W : | 161.99 g/mol | Pubchem ID : | 6019835 |
Synonyms : |
|
Num. heavy atoms : | 12 |
Num. arom. heavy atoms : | 6 |
Fraction Csp3 : | 0.11 |
Num. rotatable bonds : | 2 |
Num. H-bond acceptors : | 2.0 |
Num. H-bond donors : | 2.0 |
Molar Refractivity : | 50.63 |
TPSA : | 40.46 Ų |
GI absorption : | High |
BBB permeant : | Yes |
P-gp substrate : | No |
CYP1A2 inhibitor : | No |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -5.99 cm/s |
Log Po/w (iLOGP) : | 0.0 |
Log Po/w (XLOGP3) : | 1.83 |
Log Po/w (WLOGP) : | 0.91 |
Log Po/w (MLOGP) : | 1.17 |
Log Po/w (SILICOS-IT) : | 0.18 |
Consensus Log Po/w : | 0.82 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 1.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -2.24 |
Solubility : | 0.942 mg/ml ; 0.00582 mol/l |
Class : | Soluble |
Log S (Ali) : | -2.3 |
Solubility : | 0.812 mg/ml ; 0.00501 mol/l |
Class : | Soluble |
Log S (SILICOS-IT) : | -1.75 |
Solubility : | 2.85 mg/ml ; 0.0176 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 1.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 1.96 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P261-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H302-H315-H319-H335 | Packing Group: | N/A |
GHS Pictogram: |
![]() |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
48% | Stage #1: for 18 h; Reflux Stage #2: at 20℃; for 4 h; |
[00140] 1-Ethynyl-4-methylbenzene (0.50 mL, 3.94 mmol, 1.00 eq) and catecholborane (0.50 mL, 4.73 mmol, 1 .20 eq) were dissolved in THF (1 .5 mL) and the mixture was refluxed for 18h. The solvent was evaporated and then H20 (1 mL) was added. The suspension was vigorously stirred for 4 h at room temperature. The solid was filtered and recrystallized with water. (E)-5-phenylpent-1-en-1-ylboronic acid (309.4 mg, 1.90 mmol, 48percent) was then filtered and dried under vacuum.1H NMR (400 MHz, DMSO-d6) OH /ppm 7.73 (5, 2H), 7.36 (d, J= 7.9 Hz, 2H), 7.18 (d, J= 7.9 Hz, 2H), 6.05 (d, J= 18.3 Hz, 1H), 2.31 (5, 3H).13C NMR (101 MHz, DMSO) Oc /ppm: 146.2, 138.4, 135.4, 129.8 (20), 127.0 (20), 21 .3. |
[ 6783-05-7 ]
trans-2-Phenylvinylboronic acid
Similarity: 1.00
[ 352530-23-5 ]
(E)-(2-([1,1'-Biphenyl]-4-yl)vinyl)boronic acid
Similarity: 0.90
[ 352525-97-4 ]
(E)-(2-(Naphthalen-1-yl)vinyl)boronic acid
Similarity: 0.90
[ 6783-05-7 ]
trans-2-Phenylvinylboronic acid
Similarity: 1.00
[ 1268631-42-0 ]
(E)-(2-Methylstyryl)boronic acid
Similarity: 0.90
[ 6783-05-7 ]
trans-2-Phenylvinylboronic acid
Similarity: 1.00
[ 352530-23-5 ]
(E)-(2-([1,1'-Biphenyl]-4-yl)vinyl)boronic acid
Similarity: 0.90
[ 352525-97-4 ]
(E)-(2-(Naphthalen-1-yl)vinyl)boronic acid
Similarity: 0.90
[ 6783-05-7 ]
trans-2-Phenylvinylboronic acid
Similarity: 1.00
[ 1268631-42-0 ]
(E)-(2-Methylstyryl)boronic acid
Similarity: 0.90